Diabetes Obesity and Metabolism · 2015 · 90 citations · 29 references
MedicineEndocrinologyInternal MedicineDiabetologyMetabolic RegulationPhysiological Systems ModelingBlood Glucose MonitoringContinuous Glucose MonitoringDiabetes MellitusGlycemic ControlGlycemic MonitoringMetabolic MonitoringArtificial Pancreas MonitoringArtificial Pancreas SystemsContinuous Glucose Monitoring Guided TherapyContinuous Subcutaneous InfusionContinuous Subcutaneous Insulin InfusionGlucose MonitoringSelf-management Of HypoglycemiaSmartphone Integration
AIMS: To test in an outpatient setting the safety and efficacy of continuous subcutaneous insulin infusion (CSII) driven by a modular model predictive control (MMPC) algorithm informed by continuous glucose monitoring (CGM) measurement. METHODS: 13 patients affected by type 1 diabetes participated to a non-randomized outpatient 42-h experiment that included two evening meals and overnight periods (in short, dinner & night periods). CSII was patient-driven during dinner & night period 1 and MMPC-driven during dinner&night period 2. The study was conducted in hotels, where patients could move around freely. A CGM system (G4 Platinum; Dexcom Inc., San Diego, CA, USA) and insulin pump (AccuChek Combo; Roche Diagnostics, Mannheim, Germany) were connected wirelessly to a smartphone-based platform (DiAs, Diabetes Assistant; University of Virginia, Charlottesville, VA, USA) during both periods. RESULTS: A significantly lower percentage of time spent with glucose levels <3.9 mmol/l was achieved in period 2 compared with period 1: 1.96 ± 4.56% vs 12.76 ± 15.84% (mean ± standard deviation, p < 0.01), together with a greater percentage of time spent in the 3.9-10 mmol/l target range: 83.56 ± 14.02% vs 62.43 ± 29.03% (p = 0.04). In addition, restricting the analysis to the overnight phases, a lower percentage of time spent with glucose levels <3.9 mmol/l (1.92 ± 4.89% vs 12.7 ± 19.75%; p = 0.03) was combined with a greater percentage of time spent in 3.9-10 mmol/l target range in period 2 compared with period 1 (92.16 ± 8.03% vs 63.97 ± 2.73%; p = 0.01). Average glucose levels were similar during both periods. CONCLUSIONS: The results suggest that MMPC managed by a wearable system is safe and effective during evening meal and overnight. Its sustained use during this period is currently being tested in an ongoing randomized 2-month study.
29
Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes Camp
Moshe Phillip, Tadej Battelino, Eran Atlas et al. · New England Journal of Medicine · 2013 · 433 citations · Full text
Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms
Francis J. Doyle, Lauren M. Huyett, Joon Bok Lee et al. · Diabetes Care · 2014 · 388 citations · Full text
Fully Integrated Artificial Pancreas in Type 1 Diabetes
Marc D. Breton, Anne Farret, Daniela Bruttomesso et al. · Diabetes · 2012 · 311 citations · Full text